Iconography : Pharmacological variability of insulins degludec and glargine 300 U/mL: Equivalent or not?L MonnierC Colette
The robust effects of GLP-1 RAs to reduce body weight, usually by 2–7 kg (or % of initial body weight) on average in type 2 diabetes, have led to the exploration of GLP-1 RAs as a novel pharmacological treatment in obese but non-diabetic subjects often withimpaired fasting glucoseorgl...
Longer durationof action. Newer analogues glargine and detemir (Fig. 36.2) have become widely used, especially in type 1 diabetes. Small changes in the amino acid structure of glargine result in a significant slowing of absorption from subcutaneous depots. In contrast, detemir owes its protracted ...
Figure 2 shows results from a study in patients with type 1 diabetes conducted for a maximum of 24 hours after the subcutaneous injection of LEVEMIR. The mean time between injection and the end of pharmacological effect for insulin detemir ranged from 7.6 hours to >24 hours (24 hours was the...
pylori-related carcinogenesis may provide novel pharmacological targets for microorganism-related cancers. Hepatitis C virus has also been reported to cause permanent liver damage and hepatocellular carcinoma (Amitrano et al. 1990, Farinati et al. 1992), at least in part through oxidative stress, ...
The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis Non-alcoholic fatty liver disease (NAFLD) is an umbrella term for a series of hepatic pathologies that begin with relatively benign steatosis and can, with... D Schuppan,MD Gorrell,T Klein,... - 《Liver...
While further studies may permit a more appropriate dose of terbutaline to be selected in future, being able to reduce nocturnal basal insulin infusion for a limited period of time offers a means to reduce nocturnal hypoglycaemia without the need for additional pharmacological therapy. In those ...
Due to these pharmacological properties, it has been suggested that this type of insulin may have a role in facilitating the transition from continuous intravenous insulin infusion to subcutaneous maintenance therapy in patients with DKA. In one trial the authors hypothesized that the initiation of a...
A fixed-ratio combination of a glucagon-like peptide-1 receptor agonist (GLP-1 RA) with basal insulin, such as lixisenatide with insulin glargine (iGlarLixi), exploits the complementary mechanisms of action of each component to address hyperglycemia while mitigating potential adverse events (AEs)....
However, known long-acting insulin analogues with a structure similar to that of the compounds included in this application, constituting progress in diabetes treatment, exhibit several undesirable features, e.g. the insulin analogue widely used in therapy—insulin glargine—in spite of a microdeposit...